PUBLICAÇÕES

@article{Zanetti2021,

title = {Comparison of different fiducial markers to guide SPECT and CT image registration},

author = {T.C. Zanetti and S.Q. Brunetto and E.M. Souza and L.D.S. Sachinelli and C.D. Ramos and D.E. Zantut-Wittmann},

doi = {10.1088/1748-0221/16/05/t05003},

issn = {1748-0221},

year  = {2021},

date = {2021-05-01},

urldate = {2021-05-01},

journal = {J. Inst.},

volume = {16},

number = {05},

publisher = {IOP Publishing},

abstract = {<jats:title>Abstract</jats:title>

               <jats:p>Registration and fusion guided by the fiducial markers of

  SPECT and CT images acquired via distinct equipment is a common

  practice in several nuclear medicine centres. In this study, five

  different fiducial configurations were studied and compared for

  SPECT and CT image acquisitions: iodide-131 (<jats:sup>131</jats:sup>I) within a

  needle cap, <jats:sup>131</jats:sup>I associated with cotton, a lead and a ceramic

  aluminium sphere or mixed with an agarose solution. Fiducials that

  employed agarose mixtures presented the lowest <jats:italic>dpr</jats:italic> values

  (between 0.34 and 0.53 mm) and better homogeneous regions in both

  images to perform registration. In addition, this assembly exhibited

  the lowest global mean <jats:italic>dpr</jats:italic> and standard deviations in

  Gaussian adjustments. In comparison with the other configurations,

  the agarose <jats:italic>dpr</jats:italic> was statistically lower than that of

  cotton, ceramic aluminium and just <jats:sup>131</jats:sup>I for all the six

  landmarks. Despite its similarity with the lead sphere

  configuration, for five of the landmarks, agarose showed no

  artefacts in CT and more homogeneous regions of interest in SPECT

  images. In addition, agarose demonstrated great reproducibility to

  guide point-based registration processes.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deSouza2021,

title = {Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis},

author = {Stephan Pinheiro Macedo de Souza and Natalia Tobar and Fernanda Frasson and Efrain Araujo Perini and Carmino A. de Souza and Marcia T. Delamain and Celso Dario Ramos},

doi = {10.1097/mnm.0000000000001465},

issn = {0143-3636},

year  = {2021},

date = {2021-00-00},

urldate = {2021-00-00},

volume = {42},

number = {12},

pages = {1355--1360},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>Isolated case reports mention the uptake of radiolabeled PSMA in lymphoma. However, it is not clear if the intensity of 68Ga-PSMA expression varies among different histological subtypes or if it correlates with 18F-FDG uptake. This study compared both tracers in patients with diverse lymphoma subtypes.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>Ten patients with biopsy-proven-lymphoma underwent 18F-FDG and 68Ga-PSMA-PET/CT (maximum time interval: 6 days). Lymphoma subtypes included Hodgkin’s lymphoma (HL, three patients) and aggressive and indolent non-Hodgkin’s lymphoma (NHL, seven patients). The intensity of PSMA uptake was classified visually as low, intermediate, or high, using blood pool, liver and parotid gland uptake as references. Maximum standardized-uptake value (SUVmax) of each affected site was measured in both sets of images.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>FDG detected 59/59 involved sites in 10 patients and PSMA 47/59 sites in nine patients. PSMA uptake was generally low, regardless of the intensity of FDG uptake, but it was classified as intermediate in two patients. The median SUVmax varied from 2.0 (2.0–8.2) to 30.9 for FDG and from 1.7 (1.7–1.7) to 4.4 for PSMA, <jats:italic toggle="yes">P</jats:italic> < 0.0001. The primary lesion of one patient had a marked intralesional mismatch uptake pattern of the tracers, with areas of higher PSMA expression than FDG uptake, and vice-versa. A brain lesion was more easily identified with PSMA than with FDG images.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>HL and several NHL subtypes may present PSMA uptake. The intensity of PSMA expression is generally lower than that of FDG uptake and seems to present less variation among the different histological subtypes of lymphomas.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2021b,

title = {Intensity of bone involvement: a quantitative 18F-FDG PET/CT evaluation for monitoring outcome of multiple myeloma},

author = {Maria Emilia Seren Takahashi and Camila Mosci and Gislaine O. Duarte and Fernando V. Pericole and Konradin Metze and Irene G.H. Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001470},

issn = {0143-3636},

year  = {2021},

date = {2021-00-00},

urldate = {2021-00-00},

volume = {42},

number = {12},

pages = {1375--1381},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>The parameter intensity of bone involvement (IBI) was recently proposed to quantitatively assess patients with multiple myeloma using <jats:sup>18</jats:sup>F-fluorodeoxyglucose-PET combined with computed tomography (<jats:sup>18</jats:sup>F-FDG PET/CT) images. Here, we aimed to calculate IBI variation (ΔIBI) between two consecutive PET/CT of the same patient and verified its relationship with a subjective visual analysis of the images and with clinical outcome.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>Consecutive whole-body <jats:sup>18</jats:sup>F-FDG PET/CT performed to assess the outcomes of 29 patients diagnosed with multiple myeloma were retrospectively evaluated. ΔIBI was calculated after bone segmentation, using liver standardized uptake value as a threshold to determine metabolically active volumes in the skeleton. For each pair of consecutive PET/CTs, two nuclear medicine physicians classified visually the most recent image as PET-remission, PET-progression or PET-stable when compared to the previous examination.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>The lowest ΔIBI was –1.27 and the highest was 0.29. PET-remission was related to ΔIBI <0 (median = –0.10; –1.27 to +0.03), while PET-progression was related to ΔIBI >0 (median = 0.02; –0.07 to +0.29). ΔIBI around zero was found in images classified as PET-stable (median = 0.00; –0.08 to +0.06). Significant difference in ΔIBI was found between the three groups. Multivariate stepwise analysis showed that IBI value at diagnostic PET/CT, serum calcium and percentage of plasma cells in the bone marrow are independent prognostic factors.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>Delta IBI provides quantitative data for variations of <jats:sup>18</jats:sup>F-FDG uptake in the bone marrow during the follow-up of the patients. In addition, higher IBI values at diagnosis are associated with a higher risk of patient’s death.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2020,

title = {Radium-223 as an Approved Modality for Treatment of Bone Metastases},

author = {Ana Emília Brito and Elba Etchebehere},

doi = {10.1053/j.semnuclmed.2019.11.005},

issn = {0001-2998},

year  = {2020},

date = {2020-03-00},

urldate = {2020-03-00},

journal = {Seminars in Nuclear Medicine},

volume = {50},

number = {2},

pages = {177--192},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Camacho2019,

title = {Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma},

author = {Mariana R. Camacho and Elba Etchebehere and Natalia Tardelli and Marcia T. Delamain and Aline F.A. Vercosa and Maria E.S. Takahashi and Sergio Q. Brunetto and Irene G.H.L. Metze and Cármino A. Souza and Juliano J. Cerci and Celso D. Ramos},

doi = {10.2967/jnmt.119.231118},

issn = {1535-5675},

year  = {2020},

date = {2020-03-00},

urldate = {2020-03-00},

journal = {J. Nucl. Med.                Technol.},

volume = {48},

number = {1},

pages = {30--35},

publisher = {Society of Nuclear Medicine},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mosci2020,

title = {99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma},

author = {Camila Mosci and Fernando V. Pericole and Gislaine B. Oliveira and Marcia T. Delamain and Maria E.S. Takahashi and José Barreto C. Carvalheira and Elba C.S.C. Etchebehere and Allan O. Santos and Eliana C. M. Miranda and Mariana C.L. Lima and Barbara J. Amorim and Carmino A. de Souza and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001259},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {10},

pages = {1081--1088},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>

                                 <jats:sup>18</jats:sup>F-fluorodeoxiglucose (<jats:sup>18</jats:sup>F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. <jats:sup>99m</jats:sup>Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Materials and methods</jats:title>

            <jats:p>Sixty-two patients with recently diagnosed multiple myeloma were submitted to whole-body <jats:sup>18</jats:sup>F-FDG-PET/CT and whole-body MIBI scans plus SPECT/CT of the chest and abdomen/pelvis. Number of focal lesions, contiguous soft tissue involvement (CSTI), extramedullary lesions (EMLs) and diffuse bone marrow (BM) involvement were recorded.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>PET/CT was positive in 59 patients (95%) and MIBI SPECT/CT in 58 (93%) (<jats:italic toggle="yes">P</jats:italic> = 0.69). MIBI detected more diffuse bone marrow involvement than PET/CT (respectively 78 vs. 58% of the patients), while PET/CT demonstrated more focal lesions than MIBI SPECT/CT (81 vs. 54% of the patients) (<jats:italic toggle="yes">P</jats:italic> = 0.002). PET/CT detected EMLs in four subjects and MIBI in one subject. CSTI was found in 28 (45%) and 23 (37%) patients on PET/CT and MIBI images, respectively (<jats:italic toggle="yes">P</jats:italic> = 0.36). Three patients with lytic lesions and no FDG uptake were MIBI positive, and two subjects with lytic lesions without MIBI uptake were FDG positive.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>MIBI SPECT/CT performs similarly to <jats:sup>18</jats:sup>F-FDG-PET/CT in identifying sites of active disease in multiple myeloma staging. MIBI is more efficient than FDG for detecting the diffuse involvement of bone marrow but less efficient for detecting focal lesions. Some patients presented a ‘mismatch’ pattern of FDG/MIBI uptake.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2020,

title = {Computed tomography–based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma},

author = {Maria E.S. Takahashi and Camila Mosci and Edna M. Souza and Sérgio Q. Brunetto and Cármino de Souza and Fernando V. Pericole and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001165},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {4},

pages = {377--382},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>Quantifications in nuclear medicine are occasionally limited by the lack of standardization for defining volumes of interest (VOIs) on functional images. In the present article, we propose the use of computed tomography (CT)–based skeletal segmentation to determine anatomically the VOI in order to calculate quantitative parameters of fluorine 18 <jats:italic toggle="yes">fluorodeoxyglucose</jats:italic> (<jats:sup>18</jats:sup>F-FDG) PET/CT images from patients with multiple myeloma.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>We evaluated 101 whole-body <jats:sup>18</jats:sup>F-FDG PET/CTs of 58 patients with multiple myeloma. An initial subjective visual analysis of the PET images was used to classify the bone involvement as negative/mild, moderate, or marked. Then, a fully automated CT–based segmentation of the skeleton was performed on PET images. The maximum, mean, and SD of the standardized uptake values (SUV<jats:sub>max</jats:sub>, SUV<jats:sub>mean</jats:sub>, and SD<jats:sub>SUV</jats:sub>) were calculated for bone tissue and compared with the visual analysis.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Forty-five (44.5%), 32 (31.7%), and 24 (23.8%) PET images were, respectively, classified as negative/mild, moderate, or marked bone involvement. All quantitative parameters were significantly related to the visual assessment of bone involvement. This association was stronger for the SUV<jats:sub>mean</jats:sub> [odds ratio (OR): 10.52 (95% confidence interval (CI), 5.68–19.48); <jats:italic toggle="yes">P</jats:italic> < 0.0001] and for the SD<jats:sub>SUV</jats:sub> [OR: 5.58 (95% CI, 3.31–9.42); <jats:italic toggle="yes">P</jats:italic> < 0.001) than for the SUV<jats:sub>max</jats:sub> [OR: 1.01 (95% CI, 1.003–1.022); <jats:italic toggle="yes">P</jats:italic> = 0.003].</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>CT–based skeletal segmentation allows for automated and therefore reproducible calculation of PET quantitative parameters of bone involvement in patients with multiple myeloma. Using this method, the SUV<jats:sub>mean</jats:sub> and its respective SD correlated better with the visual analysis of <jats:sup>18</jats:sup>F-FDG PET images than SUVmax. Its value in staging and evaluating therapy response needs to be evaluated.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Riguetto2020,

title = {Fixed 30 mCi 131I-iodine therapy without recombinant human thyroid-stimulating hormone stimulation as an attractive therapeutic alternative in nontoxic nodular goiter},

author = {Cínthia Minatel Riguetto and Vivian Peraro Miguel and EJ Pavin and Bárbara Juarez Amorim and Celso Darío Ramos and Denise Engelbrecht Zantut-Wittmann},

doi = {10.1097/mnm.0000000000001213},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {8},

pages = {727--732},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Objective</jats:title>

            <jats:p>To analyze outcomes of patients with compressive nontoxic multinodular goiter after 131I-iodine 30 mCi treatment without previous use of recombinant human thyroid-stimulating hormone or methimazole.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>We evaluated fixed-dose radioiodine therapy outcomes in patients with nontoxic multinodular goiter who did not accept thyroidectomy as a therapeutic option. Laboratory thyroid function and thyroid volume estimated by ultrasound were assessed before and one year after radioiodine therapy.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Twenty euthyroid female patients received 30 mCi of 131I-iodine without recombinant human thyroid-stimulating hormone or methimazole pretreatment. Median thyroid volume and Tc-99m sodium pertechnetate thyroid uptake before radioiodine therapy were 68.05 cm<jats:sup>3</jats:sup> (31.3–295.3) and 0.5% (0.1%–1.2%), respectively. One year after radioiodine therapy, thyroid volume decreased to 55.4 cm<jats:sup>3</jats:sup> (19.8–149.9), and merely 4 patients (20%) developed hypothyroidism. Thyroid volume decreased significantly after radioiodine therapy, presenting a variation of −21.1 cm<jats:sup>3</jats:sup> (−161.3 to −0.8) and −30.61% (−73.88 to −1.02), both with <jats:italic toggle="yes">P</jats:italic> < 0.0001. Thyroid volume variation was positively correlated with thyroid uptake in Spearman’s correlation (<jats:italic toggle="yes">r</jats:italic> = 0.4730; <jats:italic toggle="yes">P</jats:italic> = 0.0352). The group satisfied with radioiodine therapy (85%, n = 17) showed a significant reduction in thyroid volume, −25.8 cm<jats:sup>3</jats:sup> (−161.3 to −6.2) and −36.74% (−73.88 to −9.95). The dissatisfied group (15%, n = 3) showed −1.0 cm<jats:sup>3</jats:sup> (−2.0 to −0.8) and −1.67% (−3.38 to −1.02) in thyroid volume, <jats:italic toggle="yes">P</jats:italic> = 0.0081. Patients that complained about dysphagia presented a lower percentage of thyroid volume decrease after radioiodine therapy, −21.97% (−70.12 to −1.02, <jats:italic toggle="yes">P</jats:italic> = 0.0430).</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusions</jats:title>

            <jats:p>A substantial reduction in thyroid volume associated with a low incidence of hypothyroidism and a high satisfaction rate support the use of conventional radioiodine therapy with a fixed dose of 30 mCi. This therapy is an attractive and cheaper therapeutic alternative in selected patients with nontoxic multinodular goiter.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2019,

title = {Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma},

author = {Maria E. S. Takahashi and Camila Mosci and Edna M. Souza and Sérgio Q. Brunetto and Elba Etchebehere and Allan O. Santos and Mariana R. Camacho and Eliana Miranda and Mariana C. L. Lima and Barbara J. Amorim and Carmino de Souza and Fernando V. Pericole and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1038/s41598-019-52740-2},

issn = {2045-2322},

year  = {2019},

date = {2019-12-00},

urldate = {2019-12-00},

journal = {Sci Rep},

volume = {9},

number = {1},

publisher = {Springer Science and Business Media LLC},

abstract = {<jats:title>Abstract</jats:title><jats:p>Many efforts have been made to standardize the interpretation of <jats:sup>18</jats:sup>F-FDG PET/CT in multiple myeloma (MM) with qualitative visual analysis or with quantitative metabolic parameters using various methods for lesion segmentation of PET images. The aim of this study was to propose a quantitative method for bone and bone marrow evaluation of <jats:sup>18</jats:sup>F-FDG PET/CT considering the extent and intensity of bone <jats:sup>18</jats:sup>F-FDG uptake: Intensity of Bone Involvement (IBI). Whole body <jats:sup>18</jats:sup>F-FDG PET/CT of 59 consecutive MM patients were evaluated. Compact bone tissue was segmented in PET images using a global threshold for HU of the registered CT image. A whole skeleton mask was created and the percentage of its volume with <jats:sup>18</jats:sup>F-FDG uptake above hepatic uptake was calculated (Percentage of Bone Involvement - PBI). IBI was defined by multiplying PBI by mean SUV above hepatic uptake. IBI was compared with visual analysis performed by two experienced nuclear medicine physicians. IBI calculation was feasible in all images (range:0.00–1.35). Visual analysis categorized PET exams into three groups (negative/mild, moderate and marked bone involvement), that had different ranges of IBI (multi comparison analysis, p < 0.0001). There was an inverse correlation between the patients’ hemoglobin values and IBI (r = −0.248;p = 0.02). IBI score is an objective measure of bone and bone marrow involvement in MM, allowing the categorization of patients in different degrees of aggressiveness of the bone disease. The next step is to validate IBI in a larger group of patients, before and after treatment and in a multicentre setting.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2018,

title = {Validation of the Semiautomatic Quantification of ^{18}F-Fluoride PET/CT Whole-Body Skeletal Tumor Burden},

author = {Ana E. Brito and Felipe Mourato and Allan Santos and Camila Mosci and Celso Ramos and Elba Etchebehere},

doi = {10.2967/jnmt.118.211474},

issn = {1535-5675},

year  = {2018},

date = {2018-12-00},

urldate = {2018-12-00},

journal = {J. Nucl. Med.                Technol.},

volume = {46},

number = {4},

pages = {378--383},

publisher = {Society of Nuclear Medicine},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Cerci2018,

title = {Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group},

author = {Juliano Júlio Cerci and Mateos Bogoni and Valeria Buccheri and Elba Cristina Sá de Camargo Etchebehere and Talita Maira Bueno da Silveira and Otavio Baiocchi and Carlos de Araujo Cunha Pereira Neto and Marcelo Tatit Sapienza and Jose Flavio Gomes Marin and José Cláudio Meneghetti and Yana Novis and Carmino Antonio de Souza and Carlos Chiattone and Marcia Torresan and Celso Dario Ramos},

doi = {10.1016/j.htct.2018.03.002},

issn = {2531-1379},

year  = {2018},

date = {2018-07-00},

urldate = {2018-07-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {40},

number = {3},

pages = {245--249},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Almeida2018,

title = {Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma},

author = {Ludmila S. Almeida and Maidane C. Araújo and Denise E. Zantut-Wittmann and Lígia V. Assumpção and Thiago F. Souza and Cleide M. Silva and Juliana L. Argenton and Allan O. Santos and Jair Mengatti and Celso D. Ramos and Elba C. Etchebehere},

doi = {10.1097/mnm.0000000000000823},

issn = {0143-3636},

year  = {2018},

date = {2018-00-00},

urldate = {2018-00-00},

volume = {39},

number = {5},

pages = {441--450},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Etchebehere2017,

title = {Therapy assessment of bone metastatic disease in the era of 223radium},

author = {Elba Etchebehere and Ana Emilia Brito and Alireza Rezaee and Werner Langsteger and Mohsen Beheshti},

doi = {10.1007/s00259-017-3734-0},

issn = {1619-7089},

year  = {2017},

date = {2017-08-00},

urldate = {2017-08-00},

journal = {Eur J Nucl Med Mol Imaging},

volume = {44},

number = {S1},

pages = {84--96},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2017,

title = {18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer},

author = {Ana E. Brito and Allan Santos and André Deeke Sasse and Cesar Cabello and Paulo Oliveira and Camila Mosci and Tiago Souza and Barbara Amorim and Mariana Lima and Celso D. Ramos and Elba Etchebehere},

doi = {10.18632/oncotarget.16418},

issn = {1949-2553},

year  = {2017},

date = {2017-05-30},

urldate = {2017-05-30},

journal = {Oncotarget},

volume = {8},

number = {22},

pages = {36001--36011},

publisher = {Impact Journals, LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1097/RLU.0000000000006145,

title = {Quantification in Clinical Nuclear Medicine: A Language Before a Number.},

author = {Ramos, Celso Dario},

journal = {Clinical Nuclear Medicine},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Quantification in Clinical Nuclear Medicine: A Language Before a Number},

author = {Celso Dario Ramos},

doi = {10.1097/RLU.0000000000006145},

journal = {Clinical Nuclear Medicine},

volume = {00},

number = {00},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Quantification in Clinical Nuclear Medicine: A Language Before a Number},

author = {Celso Dario Ramos},

doi = {10.1097/RLU.0000000000006145},

journal = {Clinical Nuclear Medicine},

volume = {00},

number = {00},

keywords = {},

pubstate = {published},

tppubtype = {article}

}